Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial

Wei Fan; HaiKou Yang; Yong Sun; Jun Zhang; Guangming Li; Ying Zheng; Yi Liu

doi:10.18632/oncotarget.13743

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial

Wei Fan, HaiKou Yang, Yong Sun _, Jun Zhang, Guangming Li, Ying Zheng and Yi Liu

PDF | HTML | How to cite

Oncotarget. 2017; 8:2356-2360. https://doi.org/10.18632/oncotarget.13743

Metrics: PDF 2318 views | HTML 3899 views | ?

Abstract

Wei Fan1, HaiKou Yang2, Yong Sun3, Jun Zhang1, Guangming Li1, Ying Zheng1, Yi Liu1

1Department of Anesthesiology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an City, Jiangsu, 223300, P.R. China

2Department of Anesthesiology, Maternal and Child Health Care Hospital of Huai’an City, Qingpu, Huai’an City, Jiangsu, 223002, P.R. China

3Department of Burn and Plastic Surgery, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an City, Jiangsu, 223300, P.R. China

Correspondence to:

Yong Sun, email: [email protected]

Keywords: ketamine, cancer, depression, suicidal ideation

Received: September 20, 2016 Accepted: November 23, 2016 Published: December 01, 2016

ABSTRACT

This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer. Forty-two patients were enrolled into the controlled trial and randomized into two groups: ketamine group and midazolam group. Patients from the two groups received a sub-anesthetic dose of racemic ketamine hydrochloride or midazolam. Suicidal ideation score, measured with the Beck Scale and suicidal part of the Montgomery-Asberg Depression Rating Scale, significantly decreased on day 1 and day 3 in ketamine-treated patients when compared to those treated with midazolam. Consistently, overall depression levels measured using the Montgomery-Asberg Depression Rating Scale indicated a significant relief of overall depression on day 1 in ketamine-treated patients. Collectively, this study provides novel information about the rapid antidepressant effect of ketamine on acute depression and suicidal ideation in newly-diagnosed cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13743

Publication Alerts

Research Papers:

Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial

Abstract